The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: Evidence and uncertainties

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 4, 2013, Pages 743-748

  Vandecasteele, S J ^a   De Vriese, A S ^a   Tacconelli, E ^b  

^a Hospital Sint Jan   (Belgium)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Continuous infusion; Dosing; Staphylococci

Indexed keywords

VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BIOFILM; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG EFFICACY; HUMAN; INOCULATION; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; KIDNEY FUNCTION; MAINTENANCE THERAPY; MATHEMATICAL MODEL; META ANALYSIS (TOPIC); MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; OTOTOXICITY; PRACTICE GUIDELINE; PRESBYACUSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SIMULATION;

ANTI-BACTERIAL AGENTS; DRUG TOXICITY; HUMANS; INFUSIONS, INTRAVENOUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 84875275931     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks495     Document Type: Review

References (38)

1. Matzke GR, Zhanel GG, Guay DR. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 1986; 11: 257-82.
2. Shorr AF. Epidemiology of staphylococcal resistance. Clin Infect Dis 2007; 45 Suppl 3: S171-6.
3. Howden BP. Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA). Intern Med J 2005; 35 Suppl 2: S136-40.
4. Rybak M, Lomaestro B, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66: 82-98.
5. Vandecasteele SJ, De Vriese AS. Recent changes in vancomycin use in renal failure. Kidney Int 2010; 77: 760-4.
6. Reynolds R, Hope R, Warner M et al. on behalf of the BSAC Extended Working Party on Resistance Surveillance. Lack of upward creep of glycopeptide MICs for methicillin-resistant Staphylococcus aureus (MRSA) isolated in the UK and Ireland 2001-07. J Antimicrob Chemother 2012; 67: 2912-8.
7. Tacconelli E, Karchmer AW, Yokoe D et al. Preventing the influx of vancomycin-resistant enterococci into health care institutions, by use of a simple validated prediction rule. Clin Infect Dis 2004; 39: 964-70.
8. CDC. Preventing the spread of vancomycin resistance - a report from the Hospital Infection Control Practices Advisory Committee prepared by the Subcommittee on Prevention and Control of Antimicrobial-Resistant Microorganisms in Hospitals; comment period and public meeting. MMWR Morb Mortal Wkly Rep 1994; 59: 25758-63.
9. Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52: e18-55.
10. Moellering RC Jr, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 1981; 94: 343-6.
11. Chuard C, Lucet JC, Rohner P et al. Resistance of Staphylococcus aureus recovered from infected foreign body in vivo to killing by antimicrobials. J Infect Dis 1991; 163: 1369-73.
12. Cui L, Iwamoto A, Lian JQ et al. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 428-38.
13. Laplante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004; 48: 4665-72.
14. Kim SH, Kim KH, Kim HB et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2008; 52: 192-7.
15. Stryjewski ME, Szczech LA, Benjamin DK Jr et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysisdependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007; 44: 190-6.
16. Forouzesh A, Moise PA, Sakoulas G. Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob Agents Chemother 2009; 53: 483-6.
17. Lowdin E, Odenholt I, Cars O. In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1998; 42: 2739-44.
18. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006; 42 Suppl 1: S35-9.
19. Moise-Broder PA, Forrest A, Birmingham MC et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43: 925-42.
20. Sakoulas G, Moise-Broder PA, Schentag J et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42: 2398-402.
21. Patel N, Pai MP, Rodvold KA et al. Vancomycin: we can't get there from here. Clin Infect Dis 2011; 52: 969-74.
22. James JK, Palmer SM, Levine DP et al. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented Gram-positive infections. Antimicrob Agents Chemother 1996; 40: 696-700.
23. Wysocki M, Delatour F, Faurisson F et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001; 45: 2460-7.
24. Lacy MK, Tessier PR, Nicolau DP et al. Comparison of vancomycin pharmacodynamics (1g every 12 or 24h) against methicillin-resistant staphylococci. Int J Antimicrob Agents 2000; 15: 25-30.
25. Wysocki M, Thomas F, Wolff MA et al. Comparison of continuous with discontinuous intravenous infusion of vancomycin in severe MRSA infections. J Antimicrob Chemother 1995; 35: 352-4.
26. Cataldo MA, Tacconelli E, Grilli E et al. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother 2012; 67: 17-24.
27. Lodise TP, Patel N, Lomaestro BM et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49: 507-14.
28. Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother 2009; 53: 4069-79.
29. Vandecasteele SJ, De BD, De Vriese AS. Implementation of a dose calculator for vancomycin to achieve target trough levels of 15-20mg/mL in persons undergoing hemodialysis. Clin Infect Dis 2011; 53: 124-9.
30. Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 2005; 56: 923-9.
31. Vardakas KZ, Mavros MN, Roussos N et al. Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with Gram-positive infections: focus on the study design. Mayo Clin Proc 2012; 87: 349-63.
32. Beibei L, Yun C, Mengli C et al. Linezolid versus vancomycin for the treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Int J Antimicrob Agents 2010; 35: 3-12.
33. Kalil AC, Murthy MH, Hermsen ED et al. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med 2010; 38: 1802-8.
34. Dodds TJ, Hawke CI. Linezolid versus vancomycin for MRSA skin and soft tissue infections (systematic review and meta-analysis). ANZ J Surg 2009; 79: 629-35.
35. Bounthavong M, Hsu DI. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis. Curr Med Res Opin 2010; 26: 407-21.
36. Logman JF, Stephens J, Heeg B et al. Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections. Curr Med Res Opin 2010; 26: 1565-78.
37. Walkey AJ, O'Donnell MR, Wiener RS. Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest 2011; 139: 1148-55.
38. Mcclaine RJ, Husted TL, Hebbeler-Clark RS et al. Meta-analysis of trials evaluating parenteral antimicrobial therapy for skin and soft tissue infections. Clin Infect Dis 2010; 50: 1120-6.